Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

The best metric is not weight, but a particularly toxic kind of fat.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...